Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls-Reference-Cited by-同舟云学术

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

Published:2021-10 Issue: Volume:55 Page:103170
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Alvarez Enrique,Nair Kavita V.,Hoyt Brian D.,Seale Rebecca A.,Sillau Stefan,Miravalle Augusto,Engebretson Eric,Schurr Brittany,Corboy John R.,Vollmer Timothy L.,Honce Justin M.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference38 articles.

1. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options;Andravizou;Auto- Immun. Highlights,2019

2. Evaluating and reducing the impact of white matter lesions on brain volume measurements;Battaglini;Hum. Brain Mapp.,2012

3. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS);Benedict;J. Int. Neuropsychol. Soc. JINS,2006

4. Clinical relevance of brain volume measures in multiple sclerosis;De Stefano;CNS Drugs,2014

5. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients;De Stefano;Mult. Scler. Houndmills Basingstoke Engl.,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cognitive Impairment in Multiple Sclerosis;Neuroimaging Clinics of North America;2024-08

2. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data;Multiple Sclerosis and Related Disorders;2024-07

3. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial;Multiple Sclerosis Journal;2024-03-12

4. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light;Multiple Sclerosis Journal;2023-08-02

5. Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging;Multiple Sclerosis Journal;2023-05